The fallout from two fatal crashes of Boeing 737 Max planes has ensnared the manufacturer's most-loyal customer: Southwest Airlines. The carrier has canceled thousands of...Airlinesread more
The Fed is expected to cut rates Wednesday, but it is unlikely to tell markets what they want to hear on future rate cuts.Market Insiderread more
Stocks rose slightly on Tuesday, but gains were capped as the Federal Reserve kicked off a two-day monetary policy meeting.US Marketsread more
Pelosi said Trump should not have tried to address China's trade practices in a way that opened Americans up to financial pain.Politicsread more
Brent crude oil jumped the most in history in the previous session after attacks on Saudi's oil industry disrupted the kingdom's production.Marketsread more
In the survey, conducted after the third in the Democratic Party's series of debate, the former vice president draws 31% compared to 25% for the Massachusetts senator. At 14%,...2020 Electionsread more
The U.S. Air Force's top general says he has not yet received direction to send additional bombers to the Middle East after what is believed to be an Iranian attack on Saudi...Defenseread more
"I believe the path to 'health care for all' is a path following the lead of the Affordable Care Act," House Speaker Nancy Pelosi tells Jim Cramer.Health and Scienceread more
E-cigarette maker Juul Labs Inc.'s sales have been halted on two websites in China, just days after it launched in the world's biggest tobacco market.Biotech and Pharmaceuticalsread more
Investors might be wary that gasoline prices will continue to rise, and are looking to take back profits by selling off shares.Retailread more
The Trump administration move on California's auto emissions standards would likely set up a fight between the White House and the state.Politicsread more
Rani Therapeutics, a start-up with a new way to turn injectable drugs like insulin into pills, has raised another $39 million, bringing its total cash haul to $100 million.
The pharmaceutical sector has long searched for ways to alleviate the $289 billion annual cost of patients that neglect to take their medication. Many of these patients will avoid needle-based injections in particular, as they can be scary, expensive and/or painful.
For that reason, the so-called "oral biologics" space presents a huge opportunity for life sciences start-ups, but it also comes with significant technological hurdles.
Rani's approach involves delivering an injection straight into the intestinal wall, which the company's CEO Mir Imran describes as "pain-free."
The company has devised a robotic pill that moves through the stomach, causing the outer case to dissolve in the small intestine.
A valve releases, fusing two previously separated chemicals to form carbon dioxide. That generates the necessary force to inject a needle-like structure made of sugar into the intestinal wall. That needle will then dissolve naturally, said Imran.
The company's technology is not currently used by patients, as it is still in the pre-clinical trials phase and has not yet been tested on humans.
Imran expects that the company will bring its technology to market in "two to three" years with an initial focus on diabetes, rheumatoid arthritis and other common, chronic conditions.
The new funding brings the company's total to $100 million. Current and existing investors include GV, Alphabet's ventures arm, as well as drug makers Novartis and Astra Zeneca.